The World Health Organization, nonprofit groups, and others have called on the biopharmaceutical industry to make its intellectual property available for the development of products to halt the COVID-19 pandemic. What is industry's view on this push? Biopharma attorneys gave their perspectives in a recent webinar.
The Federal Circuit Bar Association hosted the 7 May event, which consisted of a Q&A with IP counsel. They were...





